Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
L Guglielmetti, E Ardizzoni, M Atger, E Baudin… - Trials, 2021 - Springer
Background Treatment of multidrug-and rifampin-resistant tuberculosis (MDR/RR-TB) is
expensive, labour-intensive, and associated with substantial adverse events and poor …
expensive, labour-intensive, and associated with substantial adverse events and poor …
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
U Khan, H Huerga, AJ Khan, CD Mitnick… - BMC infectious …, 2019 - Springer
Background At a time when programs were struggling to design effective regimens for the
treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of …
treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of …
WHO recommendations on shorter treatment of multidrug-resistant tuberculosis
Comment www. thelancet. com Vol 387 June 18, 2016 2487 and meropenem-sparing and
imipenem-sparing, regimens. The majority of the M tuberculosis strains that were isolated …
imipenem-sparing, regimens. The majority of the M tuberculosis strains that were isolated …
Treatment-shortening regimens for tuberculosis: updates and future priorities
F Saluzzo, VA Adepoju, R Duarte, C Lange… - Breathe, 2023 - Eur Respiratory Soc
In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB)
treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB …
treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB …
Nine-month, all-oral regimens for rifampin-resistant tuberculosis
L Guglielmetti, U Khan, GE Velasquez, M Gouillou… - MedRxiv, 2024 - medrxiv.org
Background After a history of poor treatments for rifampin-resistant tuberculosis (RR-TB),
recent advances have resulted in shorter, more effective treatments. However, they are not …
recent advances have resulted in shorter, more effective treatments. However, they are not …
Standards for clinical trials for treating TB
BACKGROUND: The value, speed of completion and robustness of the evidence generated
by TB treatment trials could be improved by implementing standards for best practice …
by TB treatment trials could be improved by implementing standards for best practice …
What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?
M Bastard, E Sanchez-Padilla… - … of Tuberculosis and …, 2019 - ingentaconnect.com
INTRODUCTION: Identification of good prognostic marker for tuberculosis (TB) treatment
response is a necessary step on the path towards a surrogate marker to reduce TB trial …
response is a necessary step on the path towards a surrogate marker to reduce TB trial …
Bayesian uncertainty directed trial designs
S Ventz, M Cellamare, S Bacallado… - Journal of the American …, 2019 - Taylor & Francis
Most Bayesian response-adaptive designs unbalance randomization rates toward the most
promising arms with the goal of increasing the number of positive treatment outcomes during …
promising arms with the goal of increasing the number of positive treatment outcomes during …
The STREAM trial: missed opportunities and lessons for future clinical trials
Final results of the STREAM trial were presented at the 2018, 49th UnionWorld Conference
on Lung Health, held in The Hague, The Netherlands. STREAM is a randomised controlled …
on Lung Health, held in The Hague, The Netherlands. STREAM is a randomised controlled …
A comparison of clinical development pathways to advance tuberculosis regimen development
Background Current tuberculosis (TB) regimen development pathways are slow and in
urgent need of innovation. We investigated novel phase IIc and seamless phase II/III trials …
urgent need of innovation. We investigated novel phase IIc and seamless phase II/III trials …